PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 15:30:00·⟳ 抓取 15:30:27 +27s·⚡ 决策 08-31 15:31:55 +1m28s·57.1 天前
Capricor遭证券集体诉讼律所征集提醒，事项此前已广泛发布
本条是律师事务所对既有Capricor证券集体诉讼的投资者招募提醒；同一案由、集体期间、9月28日截止日和Deramiocel统计分析计划指控此前已公开传播，缺少新增监管进展、金额、公司回应或审理节点，不能形成新的做空edge。
📄 原文PR Newswire All News Releases↗ 原文
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAP…
不做 Capricor Therapeutics, Inc.（CAPR.US）
不做Capricor Therapeutics（CAPR.US）：当前消息是既有证券集体诉讼的律所征集提醒，核心指控和截止日已在8月初至8月中公开传播，缺少新增负面事实，做空edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件本身对Capricor方向偏负面，但不是新的经营或监管事实。Hagens Berman在2026-08-05和2026-08-14已发布同类集体诉讼提醒，Capricor 2026年二季报也披露7月30日证券集体诉讼及相关法律事项；本次DJS公告只是同一诉讼的又一律所征集，市场应已消化主要负面。
消息传播链
- Capricor二季报披露2026-07-30已有Nkamga v. Capricor证券集体诉讼，指控公司及高管作出重大误导陈述。
- Hagens Berman已发布CAPR证券集体诉讼提醒，列明集体期间、9月28日截止日和Deramiocel披露指控。
- PR Newswire此前已有同类律师事务所提醒，核心事实与本次DJS公告高度一致。
- 本次DJS公告为同一诉讼的投资者联系提醒，未增加新的裁判、金额或监管事实。
主要风险
- Deramiocel监管路径、既有诉讼和专利纠纷仍是Capricor的基本面风险，但本条没有新增可交易信息。
- 若后续出现法院实质裁定、FDA正式不利决定或公司披露可量化损失，需要重新评估做空。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-14 · 影响 invalidates
同一证券集体诉讼提醒此前已广泛传播，削弱以8月31日公告开新空的时效性。
检索:Capricor Therapeutics CAPR class action Deramiocel FDA statistical analysis plan August 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论；本条已因重复且无新增事实直接回避。
方向:未使用外部先例校准方向；本轮结论由同一催化重复传播和无新增事实决定。
涨幅量级:无新增交易催化，不需要用先例估算涨跌幅。
形态:律所征集类重复公告通常更接近传播噪音，不能作为新一轮价格发现锚点。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,208 字
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。